Filing Details
- Accession Number:
- 0001567619-21-011941
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-09 18:12:54
- Reporting Period:
- 2021-06-07
- Accepted Time:
- 2021-06-09 18:12:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1676725 | Ideaya Biosciences Inc. | IDYA | Pharmaceutical Preparations (2834) | 474268251 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1777415 | P. Michael Dillon | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | Svp, Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-06-07 | 1,500 | $6.92 | 100,289 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-06-07 | 1,500 | $20.22 | 98,789 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2021-06-07 | 1,500 | $0.00 | 1,500 | $6.92 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
51,000 | 2030-02-20 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $19.95 to $20.495, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.